Hussman Strategic Advisors Inc. Buys New Stake in STAAR Surgical (NASDAQ:STAA)

Hussman Strategic Advisors Inc. acquired a new stake in shares of STAAR Surgical (NASDAQ:STAA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 21,000 shares of the medical instruments supplier’s stock, valued at approximately $510,000.

Several other institutional investors have also bought and sold shares of the business. Van ECK Associates Corp lifted its position in STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares during the last quarter. Creative Planning lifted its position in STAAR Surgical by 8.0% during the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after purchasing an additional 408 shares during the last quarter. LMR Partners LLP lifted its position in STAAR Surgical by 2.2% during the third quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock valued at $1,290,000 after purchasing an additional 743 shares during the last quarter. Arcadia Investment Management Corp MI bought a new position in STAAR Surgical during the third quarter valued at $37,000. Finally, Quarry LP bought a new position in STAAR Surgical during the third quarter valued at $50,000. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Trading Down 5.2 %

Shares of STAA opened at $16.85 on Friday. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68. The company has a 50-day moving average of $22.63 and a 200 day moving average of $28.32.

Analyst Upgrades and Downgrades

STAA has been the subject of several research reports. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Wednesday, February 12th. Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Jefferies Financial Group lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Finally, Stifel Nicolaus lowered their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $26.86.

Insider Activity at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was bought at an average price of $21.50 per share, for a total transaction of $176,751.50. Following the acquisition, the insider now directly owns 10,878,007 shares of the company’s stock, valued at $233,877,150.50. This represents a 0.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders purchased 402,024 shares of company stock worth $6,936,904 in the last 90 days. 1.00% of the stock is owned by corporate insiders.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.